<DOC>
	<DOCNO>NCT02635035</DOCNO>
	<brief_summary>The primary purpose study test efficacy Lisdexamfetamine Adults With Attention Deficit Hyperactivity Disorder ( ADHD ) Sluggish Cognitive Tempo ( SCT ) . This placebo control , cross-over clinical trial oral Lisdexamfetamine Dimesylate 30-70mg/day adult attention-deficit hyper-activity disorder Sluggish Cognitive Tempo ( ACT ) . Patients assign either LDX/Placebo 10 week two week placebo washout period .</brief_summary>
	<brief_title>Shire SCT : Lisdexamfetamine Treatment ADHD SCT</brief_title>
	<detailed_description>Sluggish Cognitive Tempo ( SCT ) describe individual dreamy , spacey , slow moving , hyper active , difficulty initiate task , often seem under-motivated under-aroused . Barkley identify nine cardinal symptom SCT : 1 ) prone daydream instead concentrate ; 2 ) trouble stay alert/awake boring situation ; 3 ) easily confuse ; 4 ) easily bore ; 5 ) feeling spacey/in fog ; 6 ) frequently feel lethargic ; 7 ) under-active/having le energy others ; 8 ) slow move ; 9 ) processing information quickly/accurately . Individuals identify SCT least 5 9 symptom rat often often 9-item SCT subscale Barkley Adult ADHD Rating Scale-IV : Self-Report ( BAARS-IV ; hereafter call Barkley SCT Scale ) . This 2 Site ( NYU Mount Sinai ) Study LDX 50 adult Attention Deficit Disorder ( ADHD ) Sluggish Cognitive Tempo ( SCT ) . The study double-blind , 10-week , cross-over treatment trial LDX ( 4 week ; 30 - 70 mg/day ) vs. placebo ( 4 week ) intervene single- blind placebo washout period ( 2 week ) . During LDX treatment period , LDX treatment initiate dose 30mg/day Visit 0 titrate ( judgment investigator ) increments 20mg , base upon clinical response tolerability , 50mg/day Visit 1 70mg/day Visit 2 . Subjects receive daily dos 50mg 70mg LDX allow titrate one dosage step 20mg Visits 2-4 ( judgment investigator ) issue tolerability . The high effective dose LDX maintain Visit 4 . Patients see weekly throughout trial except placebo washout .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Male female age 1860 race ethnicity . 2 . Meets DSMIVTR criterion primary diagnosis inattentive combine type ADHD diagnose via Adult ADHD Clinician Diagnostic Scale 3 . For Sluggish Cognitive Tempo+ group Must Score ≥ 5 item Barkley Sluggish Cognitive Tempo Scale ; Must rat 3 ( `` often '' ) ( `` often '' ) total Sluggish Cognitive Tempo symptom score ≥ 26 ; must Tscore ≥ 65 Metacognition Index Motivation Subscales Behavior RatingInventory Executive Function Adult Version ( BRIEFA ) 4 . Impairment : must total score &gt; 95th percentile Barkley Functional Impairment Rating Screen ( Barkley Functional Impairment Scale ( BFIS ) . 5 . For Sluggish Cognitive Tempo group , &lt; 5 item Barkley SCT Scale must rat 3 ( `` often '' ) 4 ( `` often '' ) total SCT symptom score &lt; 26 ; must Tscore &lt; 65 Metacognition Index Motivation Subscales BRIEFA . 1 . Meets DSMIVTR criterion primary diagnosis hyperactiveimpulsive type ADHD . 2 . Any current psychiatric disorder , determine via M.I.N.I , require pharmacotherapy treatment . 3 . Current suicidal ideation history suicide attempt , base Columbia Suicide Severity Rating Scale ( CSSRS ) . 4 . Lifetime history bipolar disorder psychotic disorder per M.I.N.I 5 . Pregnant , breastfeed woman plan become pregnant . 6 . Positive urine drug toxicology exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>